Abeona Therapeutics Inc. (ABEO)
5.82
-0.04 (-0.68%)
At close: Feb 20, 2025, 3:59 PM
5.82
0.00%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 5.73 |
| Market Cap | 253.00M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.05 |
| PE Ratio (ttm) | -2.84 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.15 |
| Volume | 167,781 |
| Avg. Volume (20D) | 256,245 |
| Open | 5.86 |
| Previous Close | 5.86 |
| Day's Range | 5.79 - 5.87 |
| 52-Week Range | 3.05 - 9.01 |
| Beta | undefined |
About ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 19, 1980
Employees 84
Stock Exchange NASDAQ
Ticker Symbol ABEO
Analyst Forecast
According to 3 analyst ratings, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 209.28% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Abeona Therapeutics Inc. is scheduled to release its earnings on Mar 17, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+11.99%
Abeona Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
9 months ago
+12.14%
Abeona Therapeutics shares are trading higher. The company reported Q1 financial results.
